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Insults to cellular health cause p53 protein accumulation, and loss of p53 function leads to tumorigenesis. Thus, p53 has to be
tightly controlled. Here we report that the BTB/POZ domain transcription factor PATZ1 (MAZR), previously known for its tran-
scriptional suppressor functions in T lymphocytes, is a crucial regulator of p53. The novel role of PATZ1 as an inhibitor of the
p53 protein marks its gene as a proto-oncogene. PATZ1-deficient cells have reduced proliferative capacity, which we assessed by
transcriptome sequencing (RNA-Seq) and real-time cell growth rate analysis. PATZ1modifies the expression of p53 target genes
associated with cell proliferation gene ontology terms. Moreover, PATZ1 regulates several genes involved in cellular adhesion
andmorphogenesis. Significantly, treatment with the DNA damage-inducing drug doxorubicin results in the loss of the PATZ1
transcription factor as p53 accumulates. We find that PATZ1 binds to p53 and inhibits p53-dependent transcription activation.
We examine the mechanism of this functional inhibitory interaction and demonstrate that PATZ1 excludes p53 fromDNA bind-
ing. This study documents PATZ1 as a novel player in the p53 pathway.
Wild-type (WT) p53 is a stress-responsive, sequence-specifictranscription factor that inhibits the cell cycle, promotes
senescence, and, if the insult to cellular health is not resolved,
induces apoptotic death (1). p53 mutations that allow cells to
escape this death are the most common genetic event in human
cancer (2). Alternative mechanisms of escape rely on the overex-
pression of MDM2 andMDMX, major negative regulators of p53
that keep p53 levels low under unstressed conditions through
ubiquitination-mediated degradation (3). Moreover, many DNA
tumor viruses encode proteins that can inactivate p53 (2).
However, the list of p53 regulators is far from complete. Vari-
ous stress conditions result in the upregulation of p53, con-
trolled by feedback loops, posttranslational modifications, and
epigenetic changes. In the present study, we aimed to find new
players that modify p53 function.
p53 is composed of an N-terminal transactivation domain
(through which it interacts with MDM2), a proline-rich domain,
central DNA binding and tetramerization domains, and a C-ter-
minal regulatory domain. p53 binds response elements (REs) in
nuclear DNA, which results in stress-induced changes (either up-
or downregulation) in gene expression. Tetrameric p53 binds REs
that are composed of two half-sites, each with a consensus of RR
RCWWGYYY, separated by 0 to 21 bases (where R is a purine, Y is
a pyrimidine, and W is either an A or T) (4). p53 REs can be
subcategorized as those that respond to low levels of wild-type
p53, those that respond to stabilized p53 after stress, and those
that respond to p53withmutations in its DNAbinding domain. A
recent study found 160 p53 REs controlling 129 genes in the hu-
man genome (5). Another study using chromatin immunopre-
cipitation (ChIP) with paired-end ditag (PET) sequencing identi-
fied 542 functional p53 binding sites in the human genome (6).
Similarly, a study usingChIP followed byRNA sequencing (ChIP-
Seq) found that 3,697 target genes were bound and differentially
regulated by p53 in doxorubicin (DOX) (Adriamycin)-treated
mouse embryonic stem cells (7). Yet another ChIP-Seq study re-
vealed that of the 3,193 genes with nearby p53 REs, 432 were
regulated by DOX in mouse embryonic fibroblasts (MEFs) (8).
In the present study, we have identified the role of a BTB-ZF
(broad-complex, tramtrack, and bric-à-brac zinc finger) tran-
scription factor, PATZ1 (POZ-AT hook-zinc finger) that inhibits
the ability of p53 to bind to its REs. PATZ1 has an N-terminal
BTB domain for protein interaction, a central DNA binding AT
hook domain, and a second, C-terminal, zinc finger (ZF) DNA
binding domain (9–11). A recent ChIP-Seq study identified that
the PATZ1 binding consensus can be either AT rich or GC rich
(12). The specificity for two different consensus sequences is likely
due to two different (AT hook and ZF) DNA binding domains.
Members of the BTB-ZF transcription factor family control
diverse yet potentially related processes in cancer, development,
and stem cell biology. PATZ1 can interact with other BTB-ZF
transcription factors such as BCL-6 andBach to control important
cell fate decisions (13, 14). While PATZ1 was originally identified
as a lymphocyte specific c-Myc-regulating transcription factor, its
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expression and function are not restricted only to T lymphocytes
(15–19). Early embryonic expression is likely functional, as
Patz1/ mice are born at a non-Mendelian frequency and are
small in size (16, 17). PATZ1 is expressed in human colon and
testicular cancer cell lines and is deleted or translocated to the
Ewing sarcoma gene (EWS) in small-cell sarcoma (9, 17, 20). The
PATZ1 protein was recently shown to be an inhibitor of p53-
dependent endothelial cell senescence and was also shown to in-
teract with p53 (17, 21).
We undertook the present study to identify factors that control
p53 function. We used state-of-the-art techniques such as tran-
scriptome sequencing (RNA-Seq) and real-time cell growth ex-
periments to show that PATZ1 promotes cellular proliferation.
We discovered that PATZ1 is regulated by DNA damage and can
bind to and inhibit the transcriptional activity of p53. We charac-
terized the interaction of p53 with PATZ1 and its alternatively
spliced variants. We found that at least one of the four known
Patz1 gene products binds to p53 and interferes with p53 function
by preventing p53DNAbinding. Even though previous studies on
PATZ1 focused on its role in T lymphocytes, we discovered the
global and unbiased effects of its absence on cell proliferation,
adhesion, and morphology. Collectively, our findings indicate
that PATZ1 is a novel regulator of p53-dependent transcription.
MATERIALS AND METHODS
Generation of MEFs. WT and Patz1/ MEFs were isolated from 13.5-
day-old embryos and analyzed at early (5) passages. All mice were bred
andmaintained in the animal facility of theMedical University of Vienna,
and animal experiments were done according to protocols approved by
the Austrian Federal Ministry for Education, Science, and Art.
Cell lines, transfections, gene transfer, and treatment. HCT116,
HCT116 p53/, HEK293T, HeLa, NIH 3T3, AKR1, EL4, 3B4.14 T-hy-
bridoma, RLM11 (a radiation-induced BALB/c thymoma cell line) (22),
and VL3.3M2 DP thymocyte (a gift from C. Guidos) (23) cell lines were
cultured inDulbecco’smodified Eagle’s medium (DMEM) or RPMI 1640
supplemented with 10% fetal bovine serum and 50g/ml each of penicil-
lin and streptomycin.HCT116 andHCT116 p53/ cells were transfected
by using polyethylenimine (PEI) (catalog number 23966; Polysciences
Inc.) with a 3:1 (wt/wt) ratio of PEI to total DNA. The appropriate
amounts of plasmid DNAwere diluted in serum-free DMEM followed by
PEI and vortexed immediately. Themixwas incubated for 15min at room
temperature and added dropwise onto cells that were split 1 day before
transfection. Lysis forWestern blotting or luciferase assays was performed
48 h after transfection.
HumanHCT116 cells weremade susceptible to retroviral infection by
transient transfection with a cDNA encoding the mouse cationic amino
acid transporter (mCAT) (Addgene plasmid 10687). Retroviruses were
produced by transfection of a Patz1 cDNA in the pBabe-Puro (Addgene
plasmid 1764) backbone with a plasmid encoding ecotropic retrovirus
envelope proteins (pCL-Eco; Addgene plasmid 12371) in the HEK293T-
Phoenix-Eco retroviral packaging cell line (24, 25). Viral supernatants
were mixed with Polybrene (hexadimethrine bromide; 8 g/ml) (catalog
number H9268; Sigma-Aldrich), incubated with target cells for 3 h at
37°C, washed, and selected for 2 weeks in puromycin (1 g/ml) (catalog
number P9620; Sigma-Aldrich). Single colonies were identified, and
PATZ1 overexpression was assessed by Western blotting. In all experi-
ments, the DNA damage-inducing cytostatic drug doxorubicin (catalog
number D1515; Sigma-Aldrich) was applied for the indicated times at a
final concentration of 1M. Interacting proteinswere treated in vitrowith
ethidium bromide (50 g/ml) (catalog number E1510; Sigma-Aldrich)
during immunoprecipitation.
Generation of shRNA-expressing cell lines. A Patz1 short hairpin
RNA (shRNA)-expressing pSM2 plasmid (RMM1766-96886118; GE
Healthcare-Open Biosystems) was modified and transferred into the
pLMP retroviral expression plasmid (EAV4679; GE Healthcare-Open
Biosystems), using EcoRI and XhoI restriction sites. Retrovirus produc-
tion, infection, and selection were performed as stated above. Silencing of
PATZ1 expression in NIH 3T3 cells was confirmed by Western blotting.
Luciferase assays. HCT116 p53/, HEK293T, and HeLa cells were
cotransfected with plasmids expressing p53, PATZ1, or PATZ1Alt with
firefly luciferase reporter constructs that contained either the pG13 pro-
moter (Addgene plasmid 16442), the mG15 promoter (Addgene plasmid
16443), the p21 gene promoter (Addgene plasmid 16451) (26), or the
Puma gene promoter (Addgene plasmid 16591) (27), together with the
renilla luciferase-encoding pRL-SV40 plasmid (Promega). Cells were har-
vested 48 h after transfection and analyzed with the Dual Luciferase re-
porter kit (catalog number E1960; Promega). Promoter activity was ana-
lyzed by normalizing firefly luciferase activity to renilla luciferase activity
and adjusted to the fold increase over background.
Expression plasmids and oligonucleotides. The cytomegalovirus
(CMV) promoter-driven FLAG-p53 expression plasmid was a kind gift
from P. Ballar, Ege University, Izmir, Turkey. We sequenced this plasmid
to ensure that the p53 cDNA that it carries is a WT allele. Patz1, Patz1Alt,
and different Patz1 truncations were cloned into pCMV-HA or pCMV-
Myc (Clontech), using the EcoRI restriction enzyme site. Patz1 and
Patz1Alt cDNAs were also cloned into the pBABE-puro plasmid by using
the EcoRI restriction enzyme site. p53 and p53 expression plasmids
were a kind gift from J. C. Bourdon, University of Dundee. The sequences
of oligonucleotides used in this study for amplification are available upon
request.
Real-time cell growth and doubling time analysis. Cell proliferation
was measured continuously with an xCELLigence real-time cell analyzer
dual plate (RTCA DP) system (ACEA Biosciences, San Diego, CA), by
seeding 5,000 cells into each well of an E-Plate View 16 tissue culture plate
in 200 l in 5% CO2 at 37°C. Cell index (CI) measurements were taken
every 15 min for up to 120 h. Doubling time analysis was restricted to the
exponential growth phase.
Bacterial expression, in vitrobinding, andEMSA.The PATZ1 cDNA
was cloned into the bacterial expression plasmid pET28GST-LIC (Add-
gene plasmid 26101) by using isothermal assembly (28). Murine PATZ1
and human p53 (Addgene plasmid 24859) were expressed in the Esche-
richia coli host strain Rosetta2 DE3(pLys-S) (29). Protein expression was
induced by the addition of 1 mM isopropyl--D-thiogalactopyranoside
(IPTG) for 2 to 3 h. E. coli extracts were prepared by incubation in lysis
buffer (25 mM Tris [pH 8.00], 500 mM NaCl, 1% Triton X-100, 10%
glycerol), followed by centrifugation at 14 krpm. Glutathione S-trans-
ferase (GST) epitope-tagged PATZ1 was immobilized on glutathione-
Sepharose beads (catalog number 17-5132-02; GE Healthcare), with or
without p53, in immunoprecipitation (IP) buffer (25mMTris [pH 8.00],
100 mM KCl, 0.1% Triton X-100, 10% glycerol) overnight at 4°C and
washed 8 times in ice-cold wash buffer (25 mM Tris [pH 8.00], 100 mM
KCl, 2% Triton X-100). Protein contents of the bead conjugates were
eluted in 1 Laemmli buffer. An electrophoretic mobility shift assay
(EMSA) was performed with biotinylated p53 DNA probes (20 fmol)
incubated with bacterial extracts containing p53 and/or PATZ1 (0.01 to
0.02 optical density at 550 nm [OD550] unit equivalents) in EMSAbinding
buffer with 1 ng poly(dA-dT) (catalog number P0883; Sigma) for 1 h at
22°C and for 30min at 4°C. Shifted bandswere visualized by using strepta-
vidin-coupled horseradish peroxidase (HRP), according to the manufac-
turer’s instructions (Lightshift chemiluminescent EMSA kit, catalog
number 20148; Thermo Scientific). The specificity of p53-dependent
bands was demonstrated by competition with 40 or 80 pmol of unbioti-
nylated p53 probe or mutant p53 probe.
Cell lysis, immunoprecipitation, and DNA pulldown. Cells were
lysed in hypotonic buffer (10 mM HEPES-KOH [pH 7.9], 2 mM MgCl2,
0.1 mM EDTA, 10 mMKCl, 0.5%NP-40) and centrifuged at 14 krpm for
10 min, and supernatants were used for cytoplasmic extracts. Pellets were
Dounce homogenized with 10 strokes in hypertonic buffer (50 mM
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HEPES-KOH [pH 7.9], 2 mM MgCl2, 0.1 mM EDTA, 50 mM KCl, 400
mM NaCl, 10% glycerol) for nuclear extraction. For immunoprecipita-
tion, nuclear lysates (from 20 106 cells) were diluted at a 1:1 ratio in IP
buffer (50 mMHEPES-KOH [pH 7.9], 5 mMMgCl2, 100 mMKCl, 0.1%
NP-40, 10% glycerol), incubated with anti-FLAG or antihemagglutinin
(anti-HA) affinity gel or anti-p53 antibody-conjugated proteinG-Sephar-
ose beads at 4°C overnight, andwashed 5 times in ice-cold wash buffer (50
mM HEPES-KOH [pH 7.9], 100 mM KCl, 2% NP-40).
For DNA pulldown, streptavidin-coupled Dynabeads (catalog num-
ber 11206D; Life Technologies, CA) were conjugated with biotinylated
double-stranded p53 probes in 1 bead-DNA binding buffer (5 mM
HEPES-KOH [pH 7.9], 1 M NaCl, and 0.5 mM EDTA) at room temper-
ature for 15 min and incubated with nuclear lysates from 3 106 cells in
1 binding buffer [10mMHEPES-KOH (pH 7.9), 50mMNaCl, 0.5mM
EDTA, 1 mM MgCl2, 20% glycerol, 0.01 g/l poly(dI/dC), 0.1 g/l
bovine serumalbumin (BSA), and 0.05%NP-40] at room temperature for
30 min. Protein contents of the bead conjugates were eluted in 1 Laem-
mli buffer. Precipitated proteins were resolved on 10% SDS-PAGE gels
and transferred onto polyvinylidene difluoride (PVDF) membranes (cat-
alog number 88518; Thermo Fisher). Blots were incubated with peroxi-
dase-coupled anti-HA, anti-FLAG, or anti-Myc antibodies; anti-PATZ1
antibody followed by protein A-peroxidase; or anti-p53 antibody fol-
lowed by anti-mouse IgG–peroxidase. Reactivity was revealed by home-
made enhanced chemiluminescence solutions made from Luminol (cat-
alog number A4685; Sigma-Aldrich) and p-coumaric acid (catalog
number C9008; Sigma-Aldrich) and visualized on SuperRX Fuji film. The
intensities of bands in the Western blots were quantified with the ImageJ
program (30).
Quantitative (real-time) reverse transcription-PCR (RT-PCR). To-
talmRNAwas reverse transcribed by using a RevertAid first-strand cDNA
synthesis kit with oligo(dT) primers (Fermentas). cDNA was amplified
for 45 cycles (10 s at 95°C, 10 s at 52°C, and 10 s at 72°C) by using
LightCycler 480 SYBR green I master mix (catalog number 04887352001;
Roche) in a LightCycler 480 II instrument. Relative expression levels were
calculated by using the 2CPmethod and normalized to the glyceralde-
hyde 3-phosphate dehydrogenase gene (Gapdh) expression level.
Site-directed mutagenesis. Patz1 site-directed mutagenesis was per-
formed by using a Phusion site-directed mutagenesis kit (catalog number
F-541; Thermo Scientific), according to the manufacturer’s instructions,
using oligonucleotides abutting the target region. Briefly, a Patz1 cDNA-
containing plasmid was amplified, phosphorylated with polynucleotide
kinase (catalog number M0201; NEB), ligated back onto itself, and trans-
formed into bacteria. The R521Y/R527Y double mutant was generated by
mutating the R521Y mutant by using R527 targeting oligonucleotides.
The identities of the mutations were confirmed by bidirectional sequenc-
ing using primers EBV-rev and CMV-fwd.
Antibodies and reagents. The following antibodies were used in this
study: anti-p53 clone 1C12 (catalog number 2524; Cell Signaling Tech-
nology), anti-PATZ1 H-300 (catalog number sc-292109; Santa Cruz Bio-
tech), high-affinity anti-HA–peroxidase (catalog number 12013819001;
Roche), monoclonal anti-FLAGM2 produced in mouse (catalog number
F3165; Sigma), anti-c-Myc–peroxidase (catalog number 11814150001;
Roche), anti-actin clone c4 (catalog number MAB1501; Merck-Milli-
pore), anti-mouse IgG–peroxidase (catalog number A9044; Sigma), mono-
clonal anti-HA–agarose (catalog number A2095; Sigma), anti-FLAG M2
affinity gel (catalog number A2220; Sigma), Dynabeads protein A for
immunoprecipitation (catalog number 1002D; Life Technologies), pro-
tein G-Sepharose beads (catalog number P3296; Sigma), and protein A-
peroxidase (catalog number P8651; Sigma).
RNA-Seq analysis. Total mRNAs from early-passage Patz1 WT or
Patz1/ MEFs were extracted by using TRIzol (catalog number
15596018; LifeTech) and poly(A) selected, and triplicate samples were
sequenced at the Beijing Genomics Institute on an Illumina HiSeq 2000
sequencing machine. Raw fastq files were uploaded to GenePattern (ver-
sion 3.8.1), and reads were mapped to the 2012 release of theMus muscu-
lus genome (GRCm38.p2) by using the Bowtie aligner (Bowtie2 version
2.1.0) (31–33). The RNASeQC module (version 2) was used to perform
quality control and to calculate metrics on aligned RNA-Seq data, includ-
ing the calculated reads per kilobase of transcript per million mapped
reads (RPKM) values for each transcript. Read counts were analyzed by
using theR environment (R 3.0.2) and theDESeq package (version 1.18.0)
according to suggestions reported previously (34). The DESeq algorithm
estimates library size and variance and detects differentially expressed
genes (DEGs) on the negative binomial distribution of the compared sam-
ples. DEGswith a fold change of	2 and a false discovery rate (FDR) value
of 0.01 were used for further analysis. To identify biological processes
regulated by PATZ1, DAVID analysis was performed for gene ontology
(GO) terms. P values were calculated with DAVID, and GO terms with P
values of0.01 were selected as being significant.
RNA-Seq data accession number. All RNA-Seq data are available in
the GEO database (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc

GSE65864) under accession number GSE65864.
RESULTS
Global effects of the absence of PATZ1 expression. To under-
stand the function of PATZ1, we studied MEFs generated from
Patz1 gene-targeted C57BL/6 mice (16). We analyzed global gene
expression in the presence or absence of Patz1 gene products by
RNA-Seq.We generatedMEFs from Patz1wild-type (WT) or tar-
geted (knockout [KO]) embryos at day 13.5 and isolated poly(A)-
tailed RNA. These RNAs were sequenced by using the Illumina
HiSeq 2000 platform and analyzed by using the R library DESeq.
We identified 187 differentially expressed genes (DEGs), of which
97 were upregulated and 90 were downregulated in the absence of
Patz1 expression (data not shown). To identify biological pro-
cesses dependent on Patz1 expression, we performed DAVID
analysis for gene ontology (GO) terms. We found unique biolog-
ical processes that were associated with neuron differentiation;
development; and, consistent with the previously identified func-
tions of PATZ1, cell adhesion, morphogenesis, and proliferation
(Fig. 1A). Notably, several genes known to be involved in cellular
proliferation and also to be downstream of the p53 pathway were
differentially regulated in the absence of PATZ1.
PATZ1 shortens cellular doubling time. Because genes re-
lated to cell proliferation were enriched among the differentially
expressed genes in Patz1-deficientMEFs, we examined the growth
rate of these cells. Patz1/MEFs proliferated significantly more
slowly than did WT MEFs (Fig. 1B). Changes in the proliferation
rate were evident by the calculated doubling time, which signifi-
cantly increased for Patz1/MEFs (data not shown). This find-
ing was consistent with the increased doubling times observed
previously for MEFs generated from independent Patz1/mice
(35). Conversely, PATZ1-overexpressing HCT116 human colon
cancer cell lines proliferated faster and had decreased doubling
times (Fig. 1C and data not shown). Furthermore, NIH 3T3 cells
stably overexpressing Patz1 cDNA displayed decreased doubling
times, while cells expressing shRNA targeting all four products of
the Patz1 gene had longer doubling times (data not shown).
It is well known that the tumor suppressor p53 controls cellular
proliferation. In our RNA-Seq analysis, among the genes enriched
inGO terms related to cell proliferation, 8 genes were significantly
affected by the absence of PATZ1. Among these genes are well-
known p53 targets such as Sfn (14-3-3) and Itgam (6, 36) (Fig.
1A). Additionally, of the total 187 DEGs that we identified by
comparing Patz1 WT and KO MEFs, 24 genes were previously
found to be basal p53 target genes (8). Moreover, 13 of these 187
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PATZ1 DEGs were identified to be doxorubicin-regulated p53
targets (data not shown). Therefore, we examined the p53 depen-
dence of the role of PATZ1 in cellular proliferation. To this end,
we analyzed the growth of p53/ HCT116 cells overexpressing
PATZ1. We found that PATZ1 was unable to enhance cellular
proliferation in p53-deficient HCT116 cells (Fig. 1D). Thus, in
various cellular systems, PATZ1 activates cellular proliferation in
a p53-dependent manner.
PATZ1 is downregulated uponDNAdamage.Themouse and
human Patz1 genes express 4 major alternatively spliced tran-
scripts: mPATZ1-004, -001, -012, and -003 (corresponding to
hPATZ1-001, -004, -002, and -003, respectively), which encode
74-, 69-, 58-, and 57-kDa proteins, respectively. We analyzed the
expression of these isoforms by exon-specific amplification and
found that all four isoforms were expressed in various mouse and
human cell lines (data not shown). In this study, we annotated the
most commonly investigated 69-kDa mPATZ1-001 (hPATZ1-004)
and 58-kDa mPATZ1-012 (hPATZ1-002) isoforms PATZ1 and
PATZ1Alt, respectively, for simplicity.
To further investigate the role of PATZ1 in p53-dependent
gene expression, we treated MEFs with the DNA damage-induc-
ing cytostatic drug DOX and studied the well-established p53 re-
sponse. As expected, p53 levels of untreated MEFs were low and
rapidly induced upon treatment with DOX (Fig. 2A, bottom). In
stark contrast, PATZ1 proteins were significantly lost after 16 h of
treatment and did not recover upon further treatment (Fig. 2A,
top). We further treated HCT116 cells with DOX and found that
PATZ1 was again lost after 24 h of treatment (Fig. 2B, top). Be-
cause PATZ1 loss correlated with p53 induction after DOX treat-
ment, we questioned whether p53 was necessary for this phenom-
enon (Fig. 2B, middle). We treated HCT116 p53/ cells with
DOX and found that PATZ1 loss was still evident even in the
absence of p53 (Fig. 2B, top). To determine if PATZ1 loss was
mediated by alterations in the steady-state levels of Patz1mRNA,
we measured mRNA levels by quantitative real-time PCR but
could not detect significant changes in the time range where
PATZ1 protein levels dramatically decrease (Fig. 2C). Thus, DOX
treatment results in the loss of PATZ1, while p53 levels dramati-
cally increase.
To reveal the significance of PATZ1 loss for p53 activity, we
FIG 1 PATZ1 controls proliferation and inhibits cellular doubling time. (A) PATZ1-regulated biological processes in MEFs. Shown are biological process GO
terms enriched in ourWTversusPatz1KODEGdata set, withP values calculated byDAVID (45). EightDEGs involved in cell proliferation are listed. The overlap
of 187 PATZ1-regulated DEGs with well-characterized basal (1,269) and doxorubicin-regulated (1,323) p53 target genes reported previously by Kenzelmann
Broz et al. is shown as a Venn diagram on the right (8). (B) PATZ1 expression is positively correlated with cell growth rate. (C) PATZ1 overexpression accelerates
the growth of HCT116 cells. (D) PATZ1 cannot increase the growth rate of HCT116 cells in the absence of p53. Growth curves of Patz1/ and wild-typeMEFs
(B), HCT116 cells (C), and HCT116 p53/ cells (D) were visualized on an xCELLigence RTCA DP system.
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examined the expression of the endogenous p21 andPUMA genes,
which are known to be induced by DNA damage in a p53-depen-
dent way. As expected, p21 and PUMA gene expression levels in-
creased upon DOX treatment in HCT116 cells. Significantly,
PATZ1 overexpression blunted this p53-dependent increase, es-
pecially at later time points where endogenous PATZ1 was lost
(Fig. 2D). We conclude that PATZ1 can inhibit p53-dependent
transcription activation.
PATZ1 interacts with p53. To identify the mechanism of the
role of PATZ1 in p53 inhibition, we assessed the direct association
of these two transcription factors. We expressed epitope-tagged
versions of these proteins in E. coli and demonstrated that PATZ1
and p53 interact in vitro in GST pulldown experiments (Fig. 3A).
We examined the subcellular localization of the long (74- and
69-kDa) and short (58- and 57-kDa) PATZ1 isoforms and found
that unlike p53, which shuttles between the cytoplasm and the
nucleus, PATZ1 isoforms remain predominantly nuclear. Nuclear
localization was independent of both DOX treatment and the
presence of p53 (data not shown). To assess whether endogenous
PATZ1 and p53 physically interact, we examined the association
between these two proteins in HCT116 cells with or without p53
expression, in the presence or absence of DOX treatment. As ex-
pected, DOX dramatically increased the levels of cellular p53 (Fig.
3B, middle). Anti-p53 immunoprecipitates immunoblotted with
an antibody against the N-terminal BTB domain revealed that the
long and short PATZ1 isoforms interact with p53. Importantly,
upon short-term DOX treatment (8 h), before PATZ1 degrada-
tion was evident (Fig. 3B, bottom), the amount of PATZ1 bound
to p53 did not change (Fig. 3B, top).
PATZ1 can bind to p53 as a heterodimer. To study this inter-
action in more detail, we overexpressed HA epitope-tagged
PATZ1 or PATZ1Alt along with FLAG epitope-tagged p53 in
HCT116 p53/ cells. We found that only PATZ1 and not the
PATZ1Alt variant could bind p53 (Fig. 3C), an unexpected result
given our above-described observation that p53 antibodies could
immunoprecipitate both long and short endogenous isoforms.
The inconsistency between the interaction specificities of the en-
dogenous and overexpressed proteins could be explained in two
ways. The endogenous short PATZ1 isoform could consist of the
hPATZ1-003 and/or PATZ1Alt variant. One possibility is that
only hPATZ1-003 but not PATZ1Alt interacts with p53. Alterna-
tively, the endogenous hPATZ1-003 and PATZ1Alt variants could
be indirectly interacting with p53 in multiprotein complexes. To
address these possibilities, we tested whether PATZ1Alt het-
FIG 2 PATZ1 is downregulated upon DNA damage. (A) Downregulation of PATZ1 in DOX-treated MEFs. Whole-cell lysates from MEFs treated with 1 M
DOX for the indicated times were immunoblotted with anti-PATZ1 (top) and anti-p53 (bottom) antibodies. The presence of PATZ1 isoforms and p53 is
indicated by arrows. (B) Downregulation of PATZ1 alternative splice variants in HCT116 (p53 WT or p53/) cells treated with 1 M DOX for the indicated
times. (Top and middle) Whole-cell lysates were immunoblotted with anti-PATZ1 (top) and anti-p53 (middle) antibodies. (Bottom) Equal loading was
confirmed by blotting of the same membrane with antiactin antibodies, revealing equal amounts of a 40-kDa actin band. (C) DOX treatment does not alter
mRNA levels of PATZ1. PATZ1 mRNAs from HCT116 p53 WT or HCT116 p53/ cells treated with 1 M DOX for the indicated times were quantified by
real-time PCR. PATZ1 expression was normalized toGapdh expression. (D) Loss of PATZ1 activates p53 function. Quantitative RT-PCR analysis reveals higher
p53-dependent gene transcript levels at time points where PATZ1 is lost upon DNA damage. Mock-infected cells express more p21 (left) and Puma (right) than
do PATZ1-overexpressing cells after 48 h of DOX treatment.
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erodimerizes with PATZ1 and indirectly coimmunoprecipitates
with p53. We overexpressed Myc-PATZ1 and HA-PATZ1Alt
along with FLAG-p53 in HCT116 p53/ cells. We found that
PATZ1 and PATZ1Alt could indeed heterodimerize (Fig. 3D,
top). Moreover, PATZ1Alt associated with p53 only in the pres-
ence of PATZ1 (Fig. 3D, second panel).
The N-terminal BTB domain is required for PATZ1-
PATZ1Alt heterodimerization. Previous studies demonstrated
that BTB domains mediate homo- or heterodimerization (37). In
fact, PATZ1 could formhomodimers by using its N-terminal BTB
domain (19). To identify the domain that is required for the
PATZ1-PATZ1Alt heterodimer, we generated various expression
constructs encoding PATZ1 truncation mutants. These trunca-
tions contained (i) PATZ1 lacking its ZF domain (Myc-ZF), (ii)
PATZ1 with only the BTB domain (Myc-BTB), or (iii) PATZ1
lacking its BTB domain (Myc-BTB) (Fig. 4A). We cotransfected
HCT116 cells with HA-PATZ1Alt with either full-length Myc-
PATZ1 or its truncated variants. All of these expression constructs
resulted in the expression of equivalent levels of truncated pro-
teins (Fig. 4B, bottom). The BTB domainwas indeed necessary for
the PATZ1-PATZ1Alt interaction, as all truncated PATZ1 vari-
ants except the truncation lacking the BTB domain bound
PATZ1Alt. In fact, the BTB domain by itself was sufficient to het-
erodimerize with the PATZ1Alt protein (Fig. 4B, top). Thus,
PATZ1 can not only homodimerize but also heterodimerize with
PATZ1Alt. Moreover, these PATZ1-PATZ1Alt heterodimers re-
tain the ability to associate with p53.
p53 binds to the C terminus of PATZ1. As p53 binds only
PATZ1 and not PATZ1Alt, we assessed the domain requirements
of the p53-PATZ1 interaction in more detail. Because the PATZ1
FIG 3 PATZ1 binds p53. (A) Interaction of bacterially expressed PATZ1 and p53. (Top) Glutathione bead capture of GST epitope-tagged PATZ1 followed by
anti-p53Western blotting reveals PATZ1-bound p53 (lane 3). (Middle and bottom) Bacterial lysates show that GST-PATZ1 (middle) andHis-p53 (bottom) are
present at equal levels. (B) Endogenous PATZ1 interacts with p53 inHCT116 cells. (Top) Anti-p53 immunoprecipitation followed by anti-PATZ1 antibody (ab)
blotting reveals the presence of long and short isoforms of PATZ1 in complex with p53 in HCT116 cells in the absence (lane 1) or presence (lane 2) of DOX
treatment. Binding is specific, as immunoprecipitates from HCT116 p53/ cells (lanes 3 and 4) do not reveal the presence of PATZ1 or PATZ1Alt. (Middle)
Anti-p53 immunoprecipitation followed by anti-p53 antibody blotting reveals that DOX treatment induces p53 expression (lanes 1 and 2). (Bottom) Lysates
show that long and short isoforms of the PATZ1 protein are expressed at equal levels. (C) Overexpressed PATZ1 interacts with overexpressed p53. (Top)
Anti-FLAG immunoprecipitation followed by anti-HA antibody blotting reveals the presence of HA-PATZ1 but not HA-PATZ1Alt in HCT116 p53/ cells
transfectedwith the indicated plasmids. (Middle and bottom) Lysates of transfected cells show thatHA-PATZ1 andHA-PATZ1Alt (middle) as well as FLAG-p53
(bottom) are expressed at equal levels in transfected cells. (D) PATZ1Alt can interact with p53 only in the presence of PATZ1. (Top) Anti-HA immunoprecipi-
tation followed by anti-Myc antibody blotting reveals the presence of a complex of Myc-PATZ1 and HA-PATZ1Alt (lanes 1 and 3). (Second panel) Anti-HA
immunoprecipitation followed by anti-FLAG antibody blotting reveals the presence of an HA-PATZ1Alt–FLAG-p53 complex only in the presence of Myc-
PATZ1 (lane 1). (Bottom panels) Lysates of transfected HCT116 p53/ cells blotted with anti-Myc, anti-HA, and anti-FLAG show that PATZ1, PATZ1Alt, and
p53 proteins are expressed at equal levels.
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and PATZ1Alt proteins are identical in their N termini and differ
only after the sixth ZF motif in their DNA binding domains, we
speculated that it was the C-terminal region of PATZ1 that medi-
ated the interactionwith p53. Indeed, only the PATZ1 truncations
that contained the C-terminal ZF domain could interact with p53
(Fig. 4C, top). We also conclude that homodimerization of
PATZ1 is not required for the p53-PATZ1 interaction, as PATZ1
lacking its BTB dimerization domain continued to bind p53 (Fig.
4C, top).
To characterize the PATZ1-p53 interaction surface, we ana-
lyzed the amino acid sequence of the C-terminal region of PATZ1,
which is necessary for p53 binding. The region of PATZ1 between
FIG 4 The C-terminal tail of PATZ1 is required for binding p53. (A) Schematic representation of PATZ1 truncations. N-terminal epitope tags are indicated by
boxes with HA orMyc. The names and expectedmolecular masses of the PATZ1 truncations are indicated on the left. (B) BTB domains are necessary for PATZ1
and PATZ1Alt heterodimerization. (Top) Anti-Myc immunoprecipitation followed by anti-HA antibody blotting reveals the presence of a complex of Myc-
PATZ1 and HA-PATZ1Alt only in cells expressing BTB containing Myc-PATZ1 proteins (lanes 1, 2, and 4). Myc-BTB cannot bind to HA-PATZ1Alt (lane 3).
(Middle and bottom) Lysates of transfected HCT116 cells blotted with anti-HA and anti-Myc show that PATZ1, truncation variants of PATZ1, and PATZ1Alt
proteins are expressed at equal levels. (C) The C-terminal ZFs of PATZ1 are necessary for p53 binding. (Top) Anti-Myc immunoprecipitation followed by
anti-FLAG antibody blotting reveals the presence of FLAG-p53 in complex with Myc-PATZ1 (lane 1) and Myc-BTB (lane 3) but not Myc-BTB (lane 2) or
Myc-ZF (lane 4) in HCT116 p53/ cells transfected with the indicated plasmids. Binding is specific, as no coimmunoprecipitation is evident in lysates lacking
FLAG-p53 (lanes 6 to 9). (Middle and bottom) Lysates of transfected cells show that FLAG-p53 (middle) and Myc-PATZ1 and its truncations (bottom) are
expressed at equal levels in transfected cells. Some Myc epitope-tagged PATZ1 truncations revealed lower-molecular-weight degradation products, but the
proteins of interest at the expected size are indicated by arrows on the right. (D) Negatively charged residues in the ZF domain are required for PATZ1-p53
binding. (Top) Anti-FLAG immunoprecipitation followed by anti-HA antibody blotting reveals the presence of HA-PATZ1 (lane 1) in complex with FLAG-p53
in HCT116 p53/ cells transfected with the indicated plasmids (top). PATZ1 with a single mutation (HA-PATZ1 SM) has attenuated binding to p53 (lane 2),
while PATZ1 with a double amino acid mutation (HA-PATZ1 DM) cannot bind p53 (lane 3). Binding is specific, as no coimmunoprecipitation is evident in
lysates lacking FLAG-p53 (lanes 5 to 8). (Middle and bottom)Lysates of transfected cells show thatHA-PATZ1 and itsmutants (middle) and FLAG-p53 (bottom)
are expressed at equal levels in transfected cells.
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ZF6 and ZF7 is highly conserved and negatively charged (data not
shown). We hypothesized that if these negatively charged amino
acids were forming an interaction surface necessary to bind p53,
large, noncharged amino acid substitutions would disrupt this
interaction. To this end, we generated single (D521Y) and double
(D521Y/D527Y) site-directed mutant versions of the HA-Patz1
cDNA. HCT116 p53/ cells transfected with either WT or mu-
tant HA-Patz1 constructs expressed equivalent levels of PATZ1
(Fig. 4D, middle). We found that residues 521 and 527 of PATZ1
were necessary for the p53 interaction because the single and dou-
ble mutants, respectively, bound p53 at only reduced (40%) or
undetectable levels (Fig. 4D).
Ethidium bromide is a known DNA intercalator that disrupts
protein-DNA interactions (38). Even though PATZ1 and p53 in-
teract in nuclear lysates, this interaction was not affected by
ethidium bromide and therefore did not require the presence of
DNA (data not shown). The PATZ1-p53 interaction was also sta-
ble in cells undergoing DNA damage (data not shown). Thus, the
interaction between PATZ1 and p53 in the nucleus requires a
negatively charged region between ZFmotifs 6 and 7 in the C-ter-
minal domain, and an alternative splice variant, PATZ1Alt, can-
not directly bind p53.
PATZ1 inhibits p53 function. To study the functional signif-
icance of the PATZ1-p53 interaction, we performed luciferase re-
porter assays.We first tested whether PATZ1 could affect the abil-
ity of p53 to activate transcription from the well-established pG13
reporter, which contains 13 copies of a consensus p53 binding site
driving luciferase gene expression. As expected, p53 specifically
activated transcription from this construct when cotransfected
into HCT116 p53/ cells (Fig. 5, top). PATZ1 or PATZ1Alt ex-
pression by itself did not activate transcription from this con-
struct, while PATZ1 and p53 coexpression resulted in a 3-fold
decrease in p53 activity. We also observed dramatic decreases in
p53-dependent transcription activation in HeLa and HEK293T
cells when PATZ1 was overexpressed (data not shown). In these
experiments, PATZ1Alt did not decrease p53 activity as effectively
as did PATZ1, consistent with its inability to interact with p53.
Furthermore, PATZ1Alt did not have a dominant negative effect
on PATZ1, as it did not interfere with the function of PATZ1 on
p53. We found that PATZ1 could also inhibit the ability of p53 to
activate transcription from the CDKN1A (p21) or BBC3 (PUMA)
gene promoters (Fig. 5, middle and bottom).
Next, we assessed the domain requirements of p53 for the in-
teraction with and inhibition by PATZ1. To this end, we used wild
type (p53) or a naturally occurring alternative splice version
(p53) missing the C-terminal regulatory domain (39). As ex-
pected, PATZ1 coexpression dramatically inhibited p53-depen-
dent transcription. In contrast, PATZ1 could not directly bind or
effectively inhibit p53 (data not shown). Thus, the interaction
between PATZ1 and p53 requires the C-terminal domains of both
proteins.
PATZ1 inhibits p53 DNA binding. To understand the mech-
anism of p53 inhibition by PATZ1, we assessed p53 DNA binding
in the presence or absence of PATZ1. We performed electropho-
retic mobility shift assays (EMSAs) with biotinylated p53 probes
(derived from the pG13 reporter) incubated with bacterial ex-
tracts containing p53 and/or PATZ1. Incubation of p53withDNA
probes resulted in a specific shifted band, the intensity of which
dramatically decreased when p53 was present together with
PATZ1 (Fig. 6A). Thus, PATZ1 directly inhibits p53 DNA bind-
ing. To study the inhibition of p53 DNA binding by PATZ1 in
detail, we overexpressed FLAG-p53 andHA-PATZ1 or PATZ1Alt
variants in HCT116 p53/ cells and performed pulldown exper-
iments with biotinylated double-stranded DNA probes that were
capturedwith streptavidin-conjugatedmagnetic beads.We found
that PATZ1, which can directly bind to p53, inhibited p53 DNA
binding 5-fold. On the other hand, PATZ1Alt, which does not
bind p53, did not inhibit p53 DNA binding. Neither PATZ1 nor
PATZ1Alt could bind directly to this p53 binding-site DNA probe
FIG 5 PATZ1 inhibits p53 function. PATZ1 inhibits p53 activity in luciferase
assays. (Top) HCT116 p53/ cells transfected with different combinations of
the pG13 p53-dependent luciferase vector and FLAG-p53, PATZ1, and
PATZ1Alt expression plasmids. p53 specifically activates the pG13 reporter
(columns 1 and 2), while PATZ1 and PATZ1Alt cannot (columns 3 and 4).
PATZ1 but not PATZ1Alt can inhibit p53 activity (columns 5 and 6). (Middle
and bottom) The same experiment was conducted with the p21 promoter
luciferase construct (middle) and the Puma promoter luciferase construct
(bottom).
Keskin et al.
1748 mcb.asm.org May 2015 Volume 35 Number 10Molecular and Cellular Biology
(p53 probe 1; identical to the EMSA probe) (Fig. 6B). PATZ1
could prevent p53 DNA binding even in the presence of
PATZ1Alt. To understand the importance of the PATZ1-p53 in-
teraction in the inhibition of p53 DNA binding, we assessed the
ability of PATZ1 site-directed mutants that cannot bind to p53 to
inhibit p53DNAbinding. Like PATZ1Alt, single and double point
mutants of PATZ1 could not effectively prevent p53DNAbinding
(Fig. 6C, left). Quantification of DNA-bound p53 demonstrated
that the ability of PATZ1 to bind p53 was directly proportional to
its affinity for p53 (Fig. 6C, right). We conclude that PATZ1 can
directly interact with p53 to prevent it from binding its consensus
DNA site.
To generalize the finding that PATZ1 inhibits p53 DNA bind-
ing, we repeated this pulldown experiment with a different DNA
probe that contained p53 binding sequences from the Gadd45
gene promoter (probe 2). Again, we observed that PATZ1 inhib-
ited p53 DNA binding (Fig. 6D). Unexpectedly, PATZ1 also
bound this DNA probe, competed with p53, and contributed to
the inhibition of p53 DNA binding (Fig. 6D, second panel). Thus,
PATZ1 can inhibit p53 DNA binding by twomechanisms: first by
forming a complex with p53 and preventing p53 DNA binding
and second by competing for some p53 binding sites and displac-
ing DNA-bound p53.
We next tested whether p53 could also inhibit PATZ1 from
binding to its specific DNA probe (from the Cd8 gene locus). In
fact, in the presence of p53, 50% less PATZ1 bound this probe
(Fig. 6E, top). Surprisingly, PATZ1Alt bound this probe more
efficiently than did PATZ1, yet p53, which is incapable of binding
PATZ1Alt, could not inhibit PATZ1Alt DNA binding (Fig. 6E,
right). Thus, PATZ1 and p53 interact to form a complex that is
incapable of binding the target sites of the individual proteins.
DISCUSSION
This study identifies the mechanism of interaction between the
inhibitory transcription factor PATZ1 and the p53 tumor sup-
pressor protein. RNA-Seq analysis demonstrates that the defi-
ciency of PATZ1 affects various biological processes, one of
which is cellular proliferation. We confirmed that PATZ1 is an
activator of proliferation with real-time measurements. More-
over, this role of PATZ1 is p53 dependent, as the proliferative
capacity of p53-deficient cells is not affected by the overexpres-
sion of PATZ1. Significantly, we find that the 69-kDa PATZ1
variant can bind p53 but that the 58-kDa PATZ1Alt variant
cannot. This interaction does not require other cellular com-
plexes, as recombinant PATZ1 and p53 continue to interact in
vitro. PATZ1 binds p53 by using a negatively charged region
buried between the sixth and seventh ZF motifs in the DNA
binding domain. In fact, we find that two aspartic acid residues
(D521 and D527) are necessary for this interaction. The inter-
action of PATZ1 with p53 inhibits p53 DNA binding and p53-
dependent transcription activation.
OurRNA-Seq experiments comparing thePatz1deficiencies of
DEGs reveal critical roles for this transcription factor in cell adhe-
sion, neuron development, morphogenesis, and cellular prolifer-
ation. The association of PATZ1 deficiency with these processes
sheds light on recent findings showing that Patz1/ mice are
born with defects in their central nervous system (35). Moreover,
the finding that Patz1/mice are small could be explained by the
list of DEGs related to proliferation in our RNA-Seq experiments
(16, 17). Consistently, our findings on the alteration of the cellular
doubling time in the presence or absence of PATZ1 support the
function of this protein in cellular proliferation. Significantly, the
identification of 33 known p53 target genes as DEGs in PATZ1
deficiency links these two transcription factors.
In this study, we find that PATZ1 proteins are sensitive toDNA
damage. At early time points after DNA damage, p53 is rapidly
induced, while PATZ1 levels remain constant, where these two
proteins coexist and interact. Thus, the decrease of PATZ1 levels is
likely a result of and not causal to p53 induction. At later time
points afterDNAdamage, the protein levels of p53 and PATZ1 are
inversely correlated.We observed that in contrast to p53-deficient
cells, those with wild-type p53 had delayed PATZ1 degradation,
especially after long exposure to genotoxic DOX. The decreases in
PATZ1 levels are not regulated by the interaction of PATZ1 with
p53, as PATZ1Alt, which does not bind to p53, is degraded with
kinetics similar to those of PATZ1. As PATZ1 promotes prolifer-
ation, its downregulation after DNA damage may point to its role
in p53-dependent cell cycle control. Consistent with this idea, we
observed that upon long-term DOX treatment, as PATZ1 protein
levels decrease, p53 target gene expression levels increase. More-
over, overexpression of PATZ1 in this setting reduces this effect.
The mechanism of DNA damage-dependent PATZ1 loss is likely
due to ubiquitination-dependent proteasomal degradation and is
currently being investigated.
PATZ1 has anN-terminal BTB domain and aC-terminal DNA
binding domain composed of ZF motifs. The BTB/POZ domain
mediates homo- and heterodimerization as well as protein-pro-
tein interactions resulting in the recruitment of corepressor com-
plexes. PATZ1 uses its BTB domain to heterodimerize with other
BTB proteins such as BCL-6 and Bach (19, 40, 41). Here we also
find that the alternatively spliced variants of PATZ1 use their BTB
domains to heterodimerize with each other. An open question is
the stoichiometry of the p53-PATZ1 complex. While PATZ1 can
clearly homo- and heterodimerize, it is not known if PATZ1, like
p53, can tetramerize.We demonstrate here that truncated PATZ1
proteins without a BTB domain, which cannot homo- or het-
erodimerize, can still bind p53 (Fig. 4C).
The inability of the p53 alternative splice variant to bind
PATZ1 indicates that PATZ1 associates with the C-terminal reg-
ulatory domain of p53. A previous in vitro binding study also
confirms that PATZ1 binds to the C-terminal domain of p53 (17).
The region surrounding amino acidK382 of p53 is homologous to
that of histone H4K20 (42). In fact, our preliminary experiments
indicate that PATZ1 could also bind to H4K20. This is precisely
the region that 53BP1 recognizes in both p53 and histone H4,
suggesting that PATZ1 can potentially compete with 53BP1 for
p53 binding (43, 44). 53BP1 uses its Tudor domain to bind p53;
however, PATZ1 does not present any homology to Tudor do-
mains.
We find that PATZ1 can bind p53, independent of DOX-in-
duced DNA damage. Induction of DNA damage stabilizes and
dramatically increases the amount of nuclear p53; however, the
amount of PATZ1 that binds to p53 before and after DNAdamage
remains constant. Thus, it is possible that limiting PATZ1 levels
determine the amount of PATZ1-p53 complexes. If this is the case,
we would expect to find an abundant pool of PATZ1-unbound
p53 in stressed cells.
Of the two p53 REs that we used in this study, probe 1
contains only one decamer half-site, while probe 2 has two
adjacent decamer half-sites (from the pG13 artificial reporter
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and the Gadd45 gene promoter, respectively). Binding of p53
to both of these probes is inhibited by its association with
PATZ1, as shown by EMSA and DNA pulldown experiments.
Our site-directed mutagenesis experiments reveal that the
amount of probe-bound p53 is inversely correlated with the
affinity of PATZ1 for p53. Conversely, p53 inhibits the binding
of PATZ1 to probes containing its REs. Surprisingly, we find
that PATZ1 can also bind p53 probe 2, effectively excluding
p53 from its target site. Thus, PATZ1 can inhibit p53 DNA
binding in two ways. First, PATZ1-bound p53 cannot bind its
consensus DNA binding sites; second, PATZ1 can compete for
DNA probes containing some p53 sites.
p53 binds its REs as tetramers (Fig. 7A and B). Here we
demonstrate that PATZ1 homodimers or PATZ1-PATZ1Alt
heterodimers form complexes with p53 and remove it from
DNA (Fig. 7C). In return, p53 can also remove PATZ1 from its
binding sites. These findings indicate that PATZ1 and p53 form
a complex that is incapable of binding DNA. The selective de-
regulation of p53 target genes in PATZ1-deficient cells ob-
served by RNA-Seq correlates with the inhibitory effect of
PATZ1 on p53 DNA binding in pulldown experiments. This
study definitively reports that the BTB-ZF transcription factor
PATZ1 can interact with and inhibit the DNA binding and
transcriptional activity of p53.
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FIG 6 PATZ1 inhibits p53 DNA binding. (A) p53 DNA binding in EMSAs is inhibited by PATZ1. Incubation of bacterially expressed His-tagged p53 with
biotinylated p53 probes reveals a specific shifted band (lane 2). The specificity of this bandwas demonstrated by competition using an unlabeled p53 probe (lanes
3 and 4) and an unlabeled mutant p53 probe (lanes 5 and 6). Decreased levels of p53-dependent shifted bands are evident in the presence of PATZ1 (lanes 7 and
8). Triangles represent 2-fold increasing amounts of PATZ1 and competitor probes. *ns indicates a nonspecific band that cannot be competed away with
competitor probes. (B) The PATZ1-p53 interaction inhibits p53 DNA binding to probe 1, derived from the pG13 p53 reporter. (Top and second panels)
Precipitation followed by anti-FLAG (top) or anti-HA (second panel) antibody blotting reveals the presence ofDNA-bound FLAG-p53 but notHA-PATZ1 (top,
lane 1). FLAG-p53 continues to bind to DNA in the presence of HA-PATZ1Alt (top, lane 5) but not HA-PATZ1 (lane 4). (Third and bottom panels) Lysates of
transfected cells show that FLAG-p53 (third panel) andHA-PATZ1 andHA-PATZ1Alt (bottom) are expressed at equal levels in transfected cells. The intensities
of the relevant bands were quantified and normalized to the intensity of the lane with FLAG-p53 alone (indicated as values below the top panel). (C) PATZ1
mutants that do not bind p53 cannot inhibit p53 DNA binding. (Top and second panels) Precipitation followed by anti-FLAG (top) or anti-HA (second panel)
antibody blotting reveals the presence of DNA-bound FLAG-p53 (lane 1). FLAG-p53 continues to bind to DNA in the presence of HA-PATZ1DM (lane 7). Less
FLAG-p53 is bound to DNA in the presence of HA-PATZ1 SM (lane 6), and dramatically reduced binding is seen in the presence of HA-PATZ1 (lane 5). (Third
and bottom panels) Lysates of transfected cells show that FLAG-p53 (third panel) and HA-PATZ1 and the single and double mutants HA-PATZ1 SM and DM,
respectively (bottom), are expressed at equal levels in transfected cells. The intensities of the relevant bands were quantified and normalized to the intensity of the
lane with FLAG-p53 alone (indicated as values below the top panel). (D) The PATZ1-p53 interaction inhibits p53 DNA binding to alternative probes (probe 2;
derived from the Gadd45 promoter). (Top and second panels) Precipitation followed by anti-FLAG (top) or anti-HA (second panel) antibody blotting reveals the
presence ofDNA-boundFLAG-p53 (top, lane 1), and surprisingly,HA-PATZ1 (secondpanel, lane 2). FLAG-p53 (top, compare lanes 1 and3) andHA-PATZ1 (second
panel, compare lanes2and3)cannotbindto thisDNAprobeasefficiently in thepresenceof theotherprotein. (Thirdandbottompanels)Lysatesof transfectedcells show
that FLAG-p53 (third panel) and HA-PATZ1 (bottom) are expressed at equal levels in transfected cells. The intensities of the relevant bands were quantified and
normalized to the intensity of the lanewith FLAG-p53 alone (indicated as values below the top panel). (E) The PATZ1-p53 interaction inhibits PATZ1DNAbinding to
PATZ1 probes. (Top and second panels) Precipitation followed by anti-HA (top) or anti-FLAG (second panel) antibody blotting reveals the presence of DNA-bound
HA-PATZ1 or HA-PATZ1Alt (top, lanes 1 and 2) but not FLAG-p53 (second panel, lane 3). HA-PATZ1 cannot bind to its probe in the presence of FLAG-p53 as
efficiently (top, lane 4). However, the presence of FLAG-p53 does not affect DNA binding of PATZ1Alt (top, lane 5). (Third and bottom panels) Lysates of transfected
cells showthatFLAG-p53(bottom)andHA-PATZ1andHA-PATZ1Alt (thirdpanel) areexpressedat equal levels in transfectedcells.The intensitiesof the relevantbands
were quantified andnormalized to the intensity of the lanewithHA-PATZ1alone (indicated as values below the toppanel). (B toE)BiotinylatedDNAprobes incubated
with lysates fromHCT116 p53/ cells transfected with the indicated plasmids were precipitated with streptavidin-conjugatedmagnetic beads. Pulldown experiments
were repeated at least 3 timeswith independent lysates, and averages of data for the quantitation of the bands observed inWestern blots are depicted as bar graphs on the
right. Error bars indicate standard errors of the means.
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